1,619 results match your criteria Clinical Lung Cancer[Journal]


Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.

Background: KRAS and TP53 are common mutations in non-small-cell lung cancer (NSCLC). The Lung Adjuvant Cisplatin Evaluation Biological Program group found adjuvant chemotherapy to be deleterious in patients with coexisting KRAS/TP53 mutations.

Patients And Methods: To validate these results, patients with NSCLC tested for KRAS and TP53 mutations and receiving chemotherapy for any stage NSCLC were selected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.009DOI Listing
December 2018

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

St Luke's International Hospital, Tokyo, Japan.

Background: Cabozantinib inhibits tyrosine kinases including MET, AXL, VEGFR2, RET, KIT, and ROS1 and has demonstrated antitumor activity in multiple tumor types. The primary objective of this phase 1 study (NCT01553656) was to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of cabozantinib in Japanese patients.

Patients And Methods: Patients with advanced solid tumors were enrolled at 2 sites in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.018DOI Listing
December 2018
4 Reads

Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.

Clin Lung Cancer 2018 Dec 29. Epub 2018 Dec 29.

Department of Radiation Oncology, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN. Electronic address:

Introduction/background: Many patients with early stage non-small-cell lung cancer (ES-NSCLC) undergoing stereotactic body radiation therapy (SBRT) develop metastases, which is associated with poor outcomes. We sought to identify factors predictive of metastases after lung SBRT and created a risk stratification tool.

Materials And Methods: We included 363 patients with ES-NSCLC who received SBRT; the median follow-up was 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.016DOI Listing
December 2018
1 Read

Immunotherapy for LELC: Case Report and a Focused Review.

Clin Lung Cancer 2018 Dec 21. Epub 2018 Dec 21.

Oncologie Médicale, Hôpitaux Universitaires Paris Seine-Saint-Denis, Hôpital Avicenne, Bobigny Laboratoire d'Oncoim, Oncology, Bobigny, France. Electronic address:

Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare, Epstein-Barr virus-associated tumor. LELC occurs mostly in young, Asian nonsmokers. A few hundred cases have been reported, mostly from retrospective Asian studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.008DOI Listing
December 2018
1 Read

Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.017DOI Listing
December 2018

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Department of Radiology, Samsung Medical Center, Seoul, Korea; Sungkyunkwan University School of Medicine, Seoul, Korea.

Purpose: To determine the outcomes of transthoracic rebiopsy for epidermal growth factor receptor (EGFR) mutation in patients with lung adenocarcinoma and to explore the clinical and procedure-related risk factors for the acquisition of nondiagnostic rebiopsy specimens.

Patients And Methods: We retrospectively reviewed 367 patients with lung adenocarcinoma who underwent transthoracic core needle biopsy for mutation analysis from September 2011 to October 2016. Of these, 199 patients underwent rebiopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.021DOI Listing
December 2018
1 Read

Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.

Clin Lung Cancer 2019 Jan 2. Epub 2019 Jan 2.

University of Colorado Cancer Center, Aurora, CO.

The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving atezolizumab. These results changed the standard first-line therapy for the first time in several decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.019DOI Listing
January 2019

Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 Nov 29. Epub 2018 Nov 29.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Introduction: Platinum doublet chemotherapy has represented the standard of care in advanced non-small-cell lung cancer for decades. Targeting platelet-derived growth factor receptors (PDGFR) is a potential mechanism to improve the efficacy of first-line therapy. This randomized phase 1b/2 trial investigated the addition of the anti-PDGFRα monoclonal antibody MEDI-575 to first-line carboplatin/paclitaxel (CP) chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.012DOI Listing
November 2018
2 Reads

Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases.

Clin Lung Cancer 2018 Dec 24. Epub 2018 Dec 24.

State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of the Respiratory Health, Shunde Hospital Affiliated to Guangzhou Medical University, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address:

Background: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of lung cancer that is less reported and not well-understood.

Materials And Methods: We investigated the clinical features of 85 patients with PLELC to determine the prognostic factors.

Results: PLELC preferentially affected the young (71. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.014DOI Listing
December 2018
3 Reads

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Introduction: Non-small-cell lung cancer (NSCLC) patients harboring ALK or ROS1 rearrangements invariably acquire resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs), most notably ALK G1202R and ROS1 G2032R. Lorlatinib, a novel third-generation TKI, produced remarkable results from the first-in-man phase 1 trial: an overall response rate of 46% and 50% for previously treated ALK- and ROS1-positive patients, respectively. However, the efficacy of lorlatinib has not been widely validated in Asian patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183035
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.020DOI Listing
December 2018
2 Reads

Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Divisions of Hematology and Medical Oncology, Departments of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.

There is a rising need for optimal biomarkers to better tailor treatments for patients with cancer in the era of immunotherapy. In addition to programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB), neutrophil-to-lymphocyte (NLR) is regaining interest as a biomarker in immunotherapy for its availability, accessibility, and reproducibility. High NLR, according to different thresholds, is consistently reported to correlate with poor prognosis in different treatments in several cancers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183032
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.003DOI Listing
December 2018
3 Reads

Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France; Service de Pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, GRC-04 Theranoscan, Université Paris VI, 75970 Paris, France.

Introduction: Evaluation of EGFR Mutation status for the administration of EGFR-TKIs in non-small cell lung Carcinoma (ERMETIC) was a prospective study designed to validate the prognostic value of EGFR/KRAS mutations in patients with advanced non-small-cell lung cancer (NSCLC), all receiving a first-generation tyrosine kinase inhibitor, erlotinib. ERMETIC2 was an ancillary project evaluating the clinical value of common EGFR/KRAS-mutated subclones regarding prognosis using highly sensitive molecular detection methods.

Materials And Methods: Tumor samples from 228 patients with NSCLC (59% adenocarcinoma, 37% women, and 19% never/former smokers) were available for reanalysis using alternative highly sensitive molecular techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.012DOI Listing
December 2018
2 Reads

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.

Clin Lung Cancer 2018 Dec 27. Epub 2018 Dec 27.

Department of Internal Medicine, Division of Hematology/Oncology, UC Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183035
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.015DOI Listing
December 2018
2 Reads

Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma.

Clin Lung Cancer 2018 Dec 24. Epub 2018 Dec 24.

Department of Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.013DOI Listing
December 2018
2 Reads

Role of Skip Mediastinal Lymph Node Metastasis for Patients With Resectable Non-small-cell Lung Cancer: A Propensity Score Matching Analysis.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Background: N2 disease represents a heterogeneous group of non-small-cell lung cancer (NSCLC) with varying 5-year overall survival (OS) rates. The skip N2 phenomenon is quite frequent, and its prognostic impact remains a matter of debate. The aim of this study is to further assess the clinical significance and prognostic value of skip N2 disease using propensity score matching. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183033
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.007DOI Listing
December 2018
3 Reads

Disparities in the Treatment and Outcome of Stage I Non-Small-Cell Lung Cancer in the 21st Century.

Clin Lung Cancer 2018 Nov 20. Epub 2018 Nov 20.

Department of Radiation Oncology, Institute for Academic Medicine, Research Institute, Houston Methodist Hospital, Houston, TX. Electronic address:

Background: African American (AA) individuals are less likely to receive treatment and more likely to die from cancer compared with Caucasian (C) individuals. Recent advancements in surgery and radiation have improved outcomes in early stage non-small-cell lung cancer (ESNSCLC). We studied racial disparities in ESNSCLC in the past decade. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.004DOI Listing
November 2018
2 Reads

Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.004DOI Listing
December 2018
2 Reads

Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter Study.

Clin Lung Cancer 2018 Dec 13. Epub 2018 Dec 13.

Multidisciplinary Oncology Center Antwerp, Antwerp Hospital University, Edegem, Belgium.

Introduction: Communication about the palliative setting remains a barrier for many physicians because they are afraid to harm the patient by giving bad news. We sought to determine whether this a valid concern; the influence of prognostic understanding on patients' quality of life (QoL); and which factors influence this relationship.

Methods: The present multicenter, cross-sectional study used a questionnaire to measure patients' prognostic understanding, QoL, mood, and coping strategy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183030
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.11.011DOI Listing
December 2018
3 Reads

Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Department of Hematology and Oncology, Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.006DOI Listing
December 2018
1 Read

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Clin Lung Cancer 2018 Dec 19. Epub 2018 Dec 19.

Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address:

Advanced lung adenocarcinoma with inactive liver kinase B1 (LKB1) tumor suppressor protein is associated with poor response to immune checkpoint inhibitors and molecularly targeted agents, and with dismal patient prognosis. LKB1 is a central orchestrator of cancer cell metabolism, and halts tumor growth/proliferation during metabolic stress. Recent preclinical evidence suggests that LKB1-inactive lung adenocarcinoma is highly sensitive to metformin, a safe and low-cost antidiabetic compound that inhibits mitochondrial oxidative phosphorylation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.011DOI Listing
December 2018
1 Read

A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L).

Clin Lung Cancer 2018 Dec 11. Epub 2018 Dec 11.

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

Immune-checkpoint inhibitors (ICIs) play an important role in treatment for advanced non-small-cell lung cancer. Over one-half of patients, however, have relapse. Although rechallenge treatment of anti-cancer drugs that showed efficacy in prior lines of therapy has been broadly accepted in lung cancer, evidence of efficacy of rechallenge of ICIs has been limited to anecdotal case series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.001DOI Listing
December 2018
2 Reads

Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.

Clin Lung Cancer 2018 Nov 29. Epub 2018 Nov 29.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Background: We sought reliable markers of survival and disease control among patients treated for limited-stage small-cell lung cancer (LS-SCLC).

Patients And Methods: Subjects were 122 patients given (chemo)radiotherapy for LS-SCLC at MD Anderson in 2002 through 2015. Pretreatment total lymphocyte count (TLC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were analyzed for associations with overall (OS) and progression-free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.013DOI Listing
November 2018
3 Reads

MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis.

Clin Lung Cancer 2018 Dec 12. Epub 2018 Dec 12.

Department of Pathology, CHRU Brest, Brest, France; Inserm U1053 BaRITOn, Bordeaux, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183032
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.002DOI Listing
December 2018
4 Reads

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

Clin Lung Cancer 2018 Nov 29. Epub 2018 Nov 29.

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; Harold C. Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Veterans Affairs, North Texas Health Care System, Dallas, TX. Electronic address:

Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms "primary pericardial mesothelioma," "pericardial mesothelioma," and "malignant pericardial mesothelioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.008DOI Listing
November 2018
2 Reads

Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors.

Clin Lung Cancer 2018 Dec 4. Epub 2018 Dec 4.

Department of Medicine, Royal Marsden NHS Foundation Trust, London, United Kingdom.

Background: There is an urgent need to develop a convenient and less invasive technique to monitor the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). We proposed folate receptor-based assay to count circulating tumor cells (CTCs) to predict and dynamically monitor the therapeutic response to first-line EGFR-TKIs in patients with EGFR-mutated NSCLC.

Patients And Methods: Eligible patients were enrolled, and 3 mL of blood was obtained before initial treatment, 1 month after treatment, and every 2 months thereafter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.014DOI Listing
December 2018
5 Reads
3.104 Impact Factor

Perceptions and Utilization of Lung Cancer Screening Among Smokers Enrolled in a Tobacco Cessation Program.

Clin Lung Cancer 2019 Jan 26;20(1):e115-e122. Epub 2018 Sep 26.

Kaiser Permanente Southern California, Department of Research and Evaluation, Pasadena, CA.

Background: Although lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces lung cancer mortality in high-risk patients, most of those eligible are not referred for screening. Tobacco cessation counseling may be an opportune time to educate people about LCS, but little is known about the utilization and perceptions of LCS among people undergoing tobacco cessation treatment.

Materials And Methods: We surveyed 185 current smokers, including 122 smokers between the ages of 55 and 80 years, who were attending a tobacco cessation class in a large integrated health care system regarding lung cancer risk perception and perceived benefits, harms, and barriers to LCS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.09.013DOI Listing
January 2019
1 Read

Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.

Clin Lung Cancer 2018 Nov 20. Epub 2018 Nov 20.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Biomarker Discovery Program, Mayo Clinic, Rochester, MN; The Genome Analysis Core, Center for Individualized Medicine, Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.002DOI Listing
November 2018
3 Reads

Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.

Clin Lung Cancer 2018 Nov 29. Epub 2018 Nov 29.

Thoracic Oncology Program, University of Colorado Cancer Center, Aurora, CO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.010DOI Listing
November 2018
5 Reads

High Receipt of Statins Reduces the Risk of Lung Cancer in Current Smokers With Hypercholesterolemia: The National Health Insurance Service-Health Screening Cohort.

Clin Lung Cancer 2018 Nov 29. Epub 2018 Nov 29.

Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea; Department of Family Medicine, Chungbuk National University College of Medicine, Cheongju, Chungbuk, Korea. Electronic address:

Background: The incidence and mortality of lung cancer have risen steadily with the increasing popularity of tobacco smoking. Observational studies suggest that statins, which are widely used to lower cholesterol, may prevent lung cancer; however, other studies have produced conflicting results. We investigated the effect of statin receipt on lung cancer risk in Korean men according to smoking status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.009DOI Listing
November 2018
2 Reads

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.

Clin Lung Cancer 2018 Nov 20. Epub 2018 Nov 20.

Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Background: Molecular characterization of non-small-cell lung cancer (NSCLC), defined predictive and druggable mutations that greatly modified patient prognoses. The most frequent driver mutations detected in NSCLC are epidermal growth factor receptor (EGFR) mutations, accounting for approximately 90% of exon 19 deletions and exon 21 point mutations. The other EGFR mutations are classified as uncommon or nonclassical and include exon 18 point mutations, exon 20 insertions, and combined mutations, which present different sensitivity to tyrosine kinase inhibitor (TKI) targeting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.005DOI Listing
November 2018
3 Reads

Radiologic Criteria in Predicting Pathologic Less Invasive Lung Cancer According to TNM 8th Edition.

Clin Lung Cancer 2018 Nov 15. Epub 2018 Nov 15.

Division of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.

Purpose: The Japan Clinical Oncology Group Study 0201 has proposed radiologic criteria on thin-slice computed tomography to diagnose pathologic less invasive lung adenocarcinoma that could be a candidate for sublobar resection based on the previous tumor, node, metastasis classification system (TNM). The aim of this study was to propose the new radiologic criteria for predicting pathologic less invasive cancer according to the 8th edition TNM.

Patients And Methods: We analyzed 744 patients who had peripheral clinical Tis-T1cN0M0 non-small-cell lung cancer of 3 cm or less and underwent complete resection by lobectomy from 2003 to 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.001DOI Listing
November 2018
1 Read

De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.

Clin Lung Cancer 2018 Nov 26. Epub 2018 Nov 26.

Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.

Background: De novo mesenchymal-epithelial transition (MET) amplification represents an uncommon oncogenic event in patients with non-small-cell lung cancer, and little is known about the clinicopathologic characteristics, treatment, and prognosis of these patients.

Patients And Methods: Patient data were retrospectively collected in 5 hospitals in China from 2014 to 2016. All MET amplification was identified with fluorescence in-situ hybridization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.007DOI Listing
November 2018
2 Reads

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Clin Lung Cancer 2018 Nov 20. Epub 2018 Nov 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.003DOI Listing
November 2018
1 Read

Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.

Authors:
Dipesh Uprety

Clin Lung Cancer 2018 Nov 22. Epub 2018 Nov 22.

Department of Hematology and Medical Oncology, Gundersen Health System, La Crosse, WI. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.006DOI Listing
November 2018
1 Read

Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[F]fluoroethyl)-L-tyrosine PET.

Clin Lung Cancer 2018 Nov 5. Epub 2018 Nov 5.

Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.10.011DOI Listing
November 2018
1 Read

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.

Clin Lung Cancer 2018 Oct 24. Epub 2018 Oct 24.

University of California, Davis, CA.

Introduction: Cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against MET, vascular endothelial growth factor receptor 2, AXL, ROS1, and RET was assessed in patients with non-small-cell lung carcinoma (NSCLC) as part of a phase II randomized discontinuation trial with cohorts from 9 tumor types.

Patients And Methods: Patients received cabozantinib 100 mg/day during a 12-week open-label lead-in stage. Those with stable disease per Response Evaluation Criteria in Solid Tumors version 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.10.006DOI Listing
October 2018
4 Reads

Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.

Clin Lung Cancer 2018 Nov 1. Epub 2018 Nov 1.

Department of Respiratory Medicine and Allergy, Okayama University Hospital, Okayama, Japan.

Afatinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has demonstrated a significant survival benefit over platinum-based chemotherapy in a first-line setting in advanced non-small-cell lung cancer (NSCLC) harboring EGFR exon 19 deletion. In addition, we and other groups have shown there to be favorable progression-free survival (PFS) outcomes, with acceptable toxicity profiles, with bevacizumab and first-generation EGFR-TKI combination therapy. On the basis of the above, we hypothesized that a combination of bevacizumab and afatinib could potentially improve efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.10.008DOI Listing
November 2018
3 Reads

The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.

Clin Lung Cancer 2018 Nov 14. Epub 2018 Nov 14.

Department of Radiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:

Objectives: Programmed death-ligand 1 (PD-L1) expression might serve as a predictive biomarker for immune checkpoint inhibitors in lung cancer. However, the relationship between PD-L1 expression and imaging features of lung cancer has not been fully understood.

Patients And Methods: A total of 350 patients with pathologically confirmed adenocarcinoma who received surgical treatment and had preoperative thin section computed tomography (CT) examination were included. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183029
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.012DOI Listing
November 2018
8 Reads

Spread Through Air Spaces (STAS): A New Pathologic Morphology in Lung Cancer.

Clin Lung Cancer 2018 Oct 26. Epub 2018 Oct 26.

Department of Thoracic Surgery, Zhongshan Hospital of Fudan University, Shanghai, China.

In 2015, the World Health Organization classification of lung cancer proposed the concept of spread through air spaces (STAS) as a new pattern of invasion in lung adenocarcinoma. The definition of STAS included one or more pathologic micropapillary clusters, solid nests or single cells beyond the edge of the tumor into air spaces in the surrounding lung parenchyma, and separation from the main tumor other than tumor islands. The roles of STAS has been investigated in many studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.10.007DOI Listing
October 2018
9 Reads

Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers.

Clin Lung Cancer 2018 Nov 3. Epub 2018 Nov 3.

Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO. Electronic address:

Background: Patients with multiple primary lung cancers increasingly receive multiple courses of stereotactic body radiotherapy (SBRT). We aimed to clarify the efficacy and safety of such treatments.

Patients And Methods: We reviewed a prospective lung SBRT database of patients treated for stage I non-small-cell lung cancer between June 2004 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.10.010DOI Listing
November 2018
1 Read

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.

Clin Lung Cancer 2018 Nov 2. Epub 2018 Nov 2.

Department of Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Italy.

Background: Common epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), with exon 19 deletions being associated with better outcome compared to L858R mutations. We aimed to investigate the impact of different exon 19 deletions on patient outcome in EGFR-mutant NSCLC treated with first-line TKIs.

Patients And Methods: In this retrospective analysis, 106 patients with metastatic NSCLC harboring EGFR exon 19 deletions and treated with first-line TKIs were included. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183029
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.009DOI Listing
November 2018
16 Reads

Pneumonectomy in Stage IIIA-N2 NSCLC: Should It Be Considered After Neoadjuvant Chemotherapy?

Clin Lung Cancer 2018 Oct 24. Epub 2018 Oct 24.

Division of Thoracic Surgery, European Institute of Oncology, University of Milan, Milan, Italy; University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy.

Background: Owing to the expected poor long-term outcomes and high postoperative morbidity and mortality, patients with stage IIIA-N2 tumors candidate to pneumonectomy (PN) are usually excluded from surgery. This study aims to analyze the outcome of patients who underwent PN to prove its safety and feasibility.

Patients And Methods: We retrospectively analyzed data from 233 patients who underwent PN for N2 non-small-cell lung cancer (NSCLC) between 1998 and 2015. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183026
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.005DOI Listing
October 2018
15 Reads

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Oct 11. Epub 2018 Oct 11.

Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Aix Marseille University, Inserm U911 CRO2, Marseille, France.

Background: Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non-small-cell lung cancer (NSCLC). These treatments are associated with adverse events called immune-related adverse events (IRAEs). The incidence, diagnosis, and treatment of IRAEs are quite acknowledged; however, the link between IRAEs and the efficacy of ICIs requires further clarification. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183026
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.002DOI Listing
October 2018
8 Reads

Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Oct 23. Epub 2018 Oct 23.

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA. Electronic address:

Background: BRAF mutations occur in 1% to 4% of non-small-cell lung cancer (NSCLC) cases. Previous retrospective studies have reported similar outcomes for BRAF-mutated NSCLC as compared with wild-type tumors without a known driver mutation or tumors harboring other mutations. However, select cases of prolonged survival have also been described, and thus, the natural history of BRAF-mutated NSCLC remains an area of ongoing study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183026
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.003DOI Listing
October 2018
8 Reads

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 Sep 25. Epub 2018 Sep 25.

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

Purpose: To examine clinical predictors of tumor mutational burden (TMB), to explore the association between TMB and DNA repair mutations, and to analyze TMB as a biomarker for response to immune checkpoint blockade in non-small-cell lung cancer.

Patients And Methods: TMB scores were determined retrospectively for 72 consecutive patients at our institution with next-generation sequencing comprehensive genomic profiling testing by Foundation Medicine. TMB scores were correlated with a number of clinical variables and presence of DNA repair mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.09.008DOI Listing
September 2018
2 Reads
3.104 Impact Factor

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Clin Lung Cancer 2018 Oct 11. Epub 2018 Oct 11.

Departments of Medical Oncology and Hematology (FAS) and Pathology (M-ST), University Health Network, Princess Margaret Cancer Centre, and the University of Toronto, Toronto, Ontario, Canada.

Background: Complete resection of non-small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183026
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.001DOI Listing
October 2018
8 Reads

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.

Clin Lung Cancer 2019 Jan 11;20(1):e123-e132. Epub 2018 Oct 11.

Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:

Background: Recent studies revealed MET exon 14 skipping (METex14) as a biomarker that predicts the response to MET inhibitors in non-small-cell lung cancer (NSCLC). However, METex14 genomic alterations exhibit a highly diverse sequence composition, posing a challenge for clinical diagnostic testing. This study aimed to find a reasonable diagnostic assay for METex14 and identify its clinicopathologic implications. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183026
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.10.004DOI Listing
January 2019
13 Reads

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.

Clin Lung Cancer 2018 11 26;19(6):e823-e830. Epub 2018 May 26.

Oncology at Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.

Although lung cancer prognosis remains poor for most patients, treatments developed in the past 2 decades have extended survival for many. For those with disease that responded to or those with stable disease after receipt of platinum-based chemotherapy, maintenance regimens enable continued targeting of tumors beyond the induction phase, which is limited by toxicity. This overview summarizes completed phase 3 trials of pemetrexed continuation maintenance treatment in nonsquamous, non-small-cell lung cancer with a focus on 2-year survival, and highlights similar ongoing trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.05.013DOI Listing
November 2018
5 Reads

Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.

Clin Lung Cancer 2018 11 26;19(6):484-492. Epub 2018 May 26.

Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, PR China. Electronic address:

Background: The superior efficacy of first-line treatment with gefitinib over that of standard chemotherapy was demonstrated in patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive mutation of epidermal growth factor receptor (EGFR). However, scarce evidence showing the superiority of gefitinib to chemotherapy exists regarding the postoperative adjuvant therapy of EGFR mutation-positive patients with stage II-IIIA NSCLC. To address this important gap, we undertook a retrospective study to assess the efficacy of adjuvant gefitinib versus adjuvant chemotherapy (AC) in patients with completely resected EGFR-mutant stage II-IIIA NSCLC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183012
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.05.007DOI Listing
November 2018
10 Reads

Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.

Clin Lung Cancer 2018 11 5;19(6):467-475. Epub 2018 Jun 5.

Thoracic Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address:

Background: Pemetrexed is a folate analog inhibitor for the treatment of non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma. Folic acid and vitamin B12 supplementation before initiating pemetrexed is necessary because of high rates of cytopenias without supplementation. However, the timing of supplementation has not been thoroughly investigated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183013
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.05.017DOI Listing
November 2018
11 Reads
3.104 Impact Factor